Zai Lab reports Q2 2026 results, advances zoci and ZL-1503 toward key milestones
The company reported second-quarter revenue of $106.3 million and detailed multiple regulatory and clinical steps across its oncology and immunology pipeline.
Zai Lab Limited announced financial results for the second quarter of 2026 on August 6, 2026, along with a series of pipeline updates. The company's DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan, known as zoci, received Orphan Drug Designation from the FDA in July 2026 for neuroendocrine carcinomas, followed EMA Orphan Drug Designation in June 2026 for pulmonary NECs, and FDA Fast Track Designation in May 2026 for extrapulmonary NECs, marking the drug's second Fast Track designation; in April 2026, partner Amgen began enrollment in the global Phase 1b DeLLphi-313 study combining zoci with tarlatamab in small cell lung cancer.1
Looking ahead, Zai Lab plans to report initial Phase 1 zoci data in first-line extensive-stage SCLC at ESMO 2026 in October and, pending data and regulatory discussions, start a registrational Phase 3 study in the second half of 2026; the pivotal Phase 3 DLLEVATE study in second-line plus SCLC is expected to complete enrollment in the first half of 2027, potentially supporting an accelerated approval submission; and the epNEC program may advance into registrational development in the second half of 2026 pending regulatory feedback.1
In immunology, Zai Lab completed enrollment in the single ascending dose portion of the Phase 1/1b study of ZL-1503 in healthy volunteers, with initial PK, PD, safety and immunogenicity data expected in the second half of 2026, while enrollment continues in the multiple ascending dose portion in atopic dermatitis patients.1
On the commercial side, China's NMPA approved TIVDAK (tisotumab vedotin) in June 2026 for recurrent or metastatic cervical cancer after chemotherapy, marking the first ADC approved in China for that indication.1 Zai Lab also commercially launched KarXT (xanomeline and trospium chloride) in mainland China in June 2026 for adult schizophrenia.1
Financially, total revenue was $106.3 million in the second quarter of 2026, compared to $110.0 million a year earlier, with net product revenue of $105.8 million versus $109.1 million.1 Cash, short-term investments, and current restricted cash totaled $717.5 million as of June 30, 2026, down from $761.3 million at the end of the first quarter.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.